ArticleRevista medica del Instituto Mexicano del Seguro Social2026
[Multisystem inflammatory syndrome in a young infant with lymphocytosis and reactive thrombocytosis post COVID-19: Case report].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multisystem inflammatory syndrome in children (MIS-C) is a rare, but serious complication associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, characterized by persistent fever, systemic inflammation, and multiorgan involvement. It predominantly affects school-aged children and adolescents. Reports in infants under 1 year are limited, and atypical presentations pose diagnostic challenges. Clinical case: 8-month-old male infant who presented with 10 days of persistent fever, diarrhea, and irritability. Initial laboratory findings revealed leukocytosis, marked thrombocytosis, persistent lymphocytosis, and significantly elevated liver enzymes. No mucocutaneous findings or cardiac involvement were noted. The diagnosis of MIS-C was established based on Centers for Disease Control and Prevention (CDC) criteria and confirmed by positive IgG serology for SARS-CoV-2. Treatment with intravenous immunoglobulin (IVIg), aspirin, and corticosteroids achieved a favorable clinical and biochemical evolution. Conclusions: This case highlights an atypical presentation of MIS-C in a young infant, with hematological findings that differ from classic patterns. Early recognition and standard immunomodulatory therapy led to a successful outcome. Documenting such variants is essential to expand our understanding of MIS-C in underrepresented age groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.